Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Abstract
Olaparib is recently approved as an anti-tumor agent for several cancers, including castration-resistant prostate cancer, which inhibits poly (adenosine diphosphate-ribose) polymerase, a DNA repair factor. Since olaparib is a newly approved drug, there are few reports of skin disorders that may be triggered by olaparib administration. I...
Alternative Titles
Full title
Olaparib-Induced Purpuric Drug Eruption in a Patient with Castration-Resistant Prostate Cancer
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10294207
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10294207
Other Identifiers
ISSN
1662-6575
E-ISSN
1662-6575
DOI
10.1159/000530981
